A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.

Kastriot Kastrati; Daniel Aletaha; Gerd R Burmester; Eva Chwala; Christian Dejaco; Maxime Dougados; Iain B McInnes; Angelo Ravelli; Naveed Sattar; Tanja A Stamm; Tsutomu Takeuchi; Michael Trauner; Desirée van der Heijde; Marieke J H Voshaar; Kevin Winthrop; Josef S Smolen; Andreas Kerschbaumer

doi:10.1136/rmdopen-2022-002359

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.

Kastriot Kastrati, Daniel Aletaha, Gerd R Burmester, Eva Chwala, Christian Dejaco, Maxime Dougados, Iain B McInnes, Angelo Ravelli, Naveed Sattar, Tanja A Stamm, Tsutomu Takeuchi, Michael Trauner, Desirée van der Heijde, Marieke J H Voshaar, Kevin Winthrop, Josef S Smolen, Andreas Kerschbaumer

Krankenhaus Bruneck

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

17 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	RMD OPEN
Jahrgang	8
Ausgabenummer	2
DOIs	https://doi.org/10.1136/rmdopen-2022-002359
Publikationsstatus	Veröffentlicht - 2022

Zugriff auf Dokument

10.1136/rmdopen-2022-002359

Dieses zitieren

Kastrati, K., Aletaha, D., Burmester, G. R., Chwala, E., Dejaco, C., Dougados, M., McInnes, I. B., Ravelli, A., Sattar, N., Stamm, T. A., Takeuchi, T., Trauner, M., van der Heijde, D., Voshaar, M. J. H., Winthrop, K., Smolen, J. S., & Kerschbaumer, A. (2022). A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD OPEN, 8(2). https://doi.org/10.1136/rmdopen-2022-002359

@article{0e695dfd71a6487fa7620d9debbba78e,

title = "A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.",

keywords = "ACTIVE RHEUMATOID-ARTHRITIS, MODIFYING ANTIRHEUMATIC DRUGS, ANTI-TNF THERAPY, SUBCUTANEOUS TOCILIZUMAB MONOTHERAPY, NECROSIS-FACTOR INHIBITORS, OPTICA SPECTRUM DISORDER, DOUBLE-BLIND, INADEQUATE RESPONSE, MONOCLONAL-ANTIBODY, OPEN-LABEL",

author = "Kastriot Kastrati and Daniel Aletaha and Burmester, {Gerd R} and Eva Chwala and Christian Dejaco and Maxime Dougados and McInnes, {Iain B} and Angelo Ravelli and Naveed Sattar and Stamm, {Tanja A} and Tsutomu Takeuchi and Michael Trauner and {van der Heijde}, Desir{\'e}e and Voshaar, {Marieke J H} and Kevin Winthrop and Smolen, {Josef S} and Andreas Kerschbaumer",

note = "Lehr-KH Bruneck: Hospital of Bruneck, Bruneck, Italy",

year = "2022",

doi = "10.1136/rmdopen-2022-002359",

language = "English",

volume = "8",

journal = "RMD OPEN",

issn = "2056-5933",

number = "2",

}

Kastrati, K, Aletaha, D, Burmester, GR, Chwala, E, Dejaco, C, Dougados, M, McInnes, IB, Ravelli, A, Sattar, N, Stamm, TA, Takeuchi, T, Trauner, M, van der Heijde, D, Voshaar, MJH, Winthrop, K, Smolen, JS & Kerschbaumer, A 2022, 'A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.', RMD OPEN, Jg. 8, Nr. 2. https://doi.org/10.1136/rmdopen-2022-002359

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. / Kastrati, Kastriot; Aletaha, Daniel; Burmester, Gerd R et al.
in: RMD OPEN, Jahrgang 8, Nr. 2, 2022.

Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Begutachtung

TY - JOUR

T1 - A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.

AU - Kastrati, Kastriot

AU - Aletaha, Daniel

AU - Burmester, Gerd R

AU - Chwala, Eva

AU - Dejaco, Christian

AU - Dougados, Maxime

AU - McInnes, Iain B

AU - Ravelli, Angelo

AU - Sattar, Naveed

AU - Stamm, Tanja A

AU - Takeuchi, Tsutomu

AU - Trauner, Michael

AU - van der Heijde, Desirée

AU - Voshaar, Marieke J H

AU - Winthrop, Kevin

AU - Smolen, Josef S

AU - Kerschbaumer, Andreas

N1 - Lehr-KH Bruneck: Hospital of Bruneck, Bruneck, Italy

PY - 2022

Y1 - 2022

KW - ACTIVE RHEUMATOID-ARTHRITIS

KW - MODIFYING ANTIRHEUMATIC DRUGS

KW - ANTI-TNF THERAPY

KW - SUBCUTANEOUS TOCILIZUMAB MONOTHERAPY

KW - NECROSIS-FACTOR INHIBITORS

KW - OPTICA SPECTRUM DISORDER

KW - DOUBLE-BLIND

KW - INADEQUATE RESPONSE

KW - MONOCLONAL-ANTIBODY

KW - OPEN-LABEL

U2 - 10.1136/rmdopen-2022-002359

DO - 10.1136/rmdopen-2022-002359

M3 - Review article

C2 - 36260501

SN - 2056-5933

VL - 8

JO - RMD OPEN

JF - RMD OPEN

IS - 2

ER -